Oestrogen - A new treatment approach for schizophrenia?

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  Kulkarni, Jayashri ^a  

^a Alfred Hospital ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; NEUROLEPTIC AGENT; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; MENSTRUAL CYCLE; NEUROPROTECTION; NONHUMAN; PATIENT COMPLIANCE; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 61849174635     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02373.x     Document Type: Article

References (17)

1. Häfner H. The epidemiology of beginning schizophrenia. In: WRA section of Epidemiology and Community Psychiatry Symposium; 1991 Jun 14-16; Oslo.
2. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-195.
3. Kraepelin E. Dementia praecox and paraphrenia (translated by Barclay RM, Robertson GM). Extracted from: Psychiatrie. Vol 3. 8th ed (1910). Edinburgh: Livingstone, 1919.
4. Angermeyer MC, Kühn L. Gender differences in age at onset of schizophrenia. Eur Arch Psychiatry Neurol Sci 1988; 237: 351-364.
5. Häfner H. Gender differences in schizophrenia. In: Bergemann N, Riecher-Rössler A, editors. Estrogen effects in psychiatric disorders. Vienna: Springer-Verlag, 2005: 53-94.
6. Loffler W, Häfner H, Fatkenheuer B, et al. Validation of Danish case register for schizophrenia. Acta Psychiatr Scand 1994; 90: 196-203.
7. Riecher-Rössler A, HSfner H, Stumbaum M, et al. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20: 203-214.
8. Riecher-Rössler A. Estrogens and schizophrenia. In: Bergemann N, Riecher-Rössler A, editors. Estrogen effects in psychiatric disorders. Vienna: Springer-Verlag, 2005: 31-52.
9. Fink G. The psychoprotective action of estrogen is mediated by central serotonergic as well as doparninergic mechanisms. In: Takada A, Curzon G, editors. Serotonin in the central nervous system and periphery. Amsterdam: Elsevier Science BV, 1995: 175-187.
10. Mosselman S, Polman J, Dukema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
11. Kulkarni J, de Castella A, Smith D, et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizoph Res 1996; 20: 247-252.
12. Kulkarni J, de Castella A, Riedel A, et al. Estrogen - a potential new treatment in schizophrenia. Schizophr Res 2001; 48: 137-144.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
14. Kulkarni J, cle Castella A, Fitzgerald P, et al. Estrogen in severe mental illness. A potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-960.
15. Kulkarni J. Clinical estrogen trials in patients with schizophrenia. In: Bergemann N, Riecher-Rössler A, editors. Estrogen effects in psychiatric disorders. Vienna: Springer-Verlag, 2005: 107-123.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
17. Chlebowski RT, Hendrix SL, Langer RD, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253.